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T he well-established 1 ability of CD8 + T cells to recognize and kill cancer cells is exploited by immunotherapies such as vaccines 2 , checkpoint blockade 3, 4 , and adoptive T cell therapies 5 . A CD8 + T cell encodes a unique surface TCR that recognizes 8-12-residue-long peptide epitopes presented on class I MHC molecules, also known as human leukocyte antigens (HLAs) in humans 6 . When a TCR binds a cognate peptide-MHC complex (pMHC), the associated CD247 (CD3ζ ) chains dimerize to initiate downstream signaling. Multiple signaling cascades are activated, leading to rapid gene expression driven by the transcription factors NF-κ B, AP-1, and NFAT 7 . In CD8 + T cells, TCR signaling induces the expression of early activation markers (CD69 and LAMP1), the release of cytotoxic granules, and the secretion of cytokines, ultimately killing the target cell 7 . The interaction of cognate TCR and pMHC complexes generates a high degree of specificity toward a target antigen. T cells can recognize epitopes presented by tumor cells and infiltrate the tumor microenvironment. Antitumor T cells respond to two kinds of tumor-derived epitopes: (1) public or private epitopes originating from nonmutant, tissue-specific antigens or cancer-testis antigens; and (2) private neoantigens originating from nonsynonymous mutations 8 . Both endogenous antigens and neoantigens can be used to provide immunotherapy targets.
Scientists have made considerable progress toward understanding the T cell repertoire 9 and function 10 by means of high-throughput genomics, transcriptomics, and proteomics. However, one of the bottlenecks in the field of tumor immunology is the identification of the antigen recognized by a particular antitumor CD8 + T cell. Several techniques have been developed to identify cognate antigens for T cells. The most common approach uses pMHC multimers to identify antigen-specific T cells by flow cytometry 11, 12 . Antigen discovery using pMHC multimers requires ab initio knowledge of the antigenic landscape and is not scalable beyond 10 3 antigens, but it can identify multiple antigenic specificities simultaneously. This approach has been used to discover public tumor antigens 13 and private neoantigens 12, 14 . A recently reported approach uses yeast display of epitope libraries for antigen discovery 15 . However, this approach is technically challenging because of the requirement of soluble TCR and does not represent the physiological TCR-pMHC interaction, although it is antigen agnostic and scalable to 10 6 -10 8 epitopes 16 . These limitations underscore the need for new techniques for T cell antigen discovery.
Here we present cell-based platforms for T cell antigen discovery. We describe SABRs, chimeric receptors that allow the identification of a successful TCR-pMHC interaction. We report a platform for a T cell antigen discovery strategy based on screening of a large number of antigens via SABR libraries.
Results
Signaling and antigen-presenting bifunctional receptors. T cell activation after recognition of a target antigen induces detectable gene expression. However, as MHC molecules lack signaling domains, the detection of recognized antigen-presenting cells is challenging. To address this, we constructed chimeric receptors called SABRs. The extracellular domain of a SABR is a covalently linked peptide-β 2-microglobulin-MHC trimer 17 fused to an intracellular CD3ζ signaling domain with a CD28 costimulatory domain. We constructed two variations of SABRs, SABR-F and SABR-E, that contained the entire MHC molecule and only the extracellular part of the MHC molecule, respectively ( Supplementary Fig. 1a) . We hypothesized that upon interaction with a TCR, a SABR presenting T cell antigen discovery via signaling and antigen-presenting bifunctional receptors Alok V. Joglekar 1 
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NATuRe MeTHoDS its cognate antigen would induce an intracellular signal (Fig. 1a) . To detect the signal induced by SABRs, we used NFAT-GFPJurkat cells, which express GFP after receiving a signal via CD3ζ . We transduced NFAT-GFP-Jurkat cells with SABRs presenting the ELAGIGILTV epitope (from the MART1/MLANA protein) on HLA-A*0201 (hereinafter referred to as A2-MART1-SABR) or the KRWIILGLNK epitope (KK10, from the HIV-1 gag protein) from HIV-1 on HLA-B*2705 (hereinafter referred to as B27-KK10-SABR). We co-incubated transduced NFAT-GFP-Jurkat cells with Jurkat cells that expressed TCRs, and measured GFP expression by flow cytometry after 8 h. Specifically, we used F5 (recognizes A2-MART1 18 ), EC27 (recognizes B27-KK10 19 ), and SL9 (recognizes A2-SLYNTVATL 20 ) TCRs or untransduced Jurkat cells. GFP expression was detected only in coculture assays with the cognate TCR-SABR-F pairs ( Fig. 1b and Supplementary Fig. 1b) . The SABR-F construct showed higher signal than SABR-E, and therefore was used for further experiments ( Supplementary Fig. 1c ). SABR signaling was titratable and sensitive enough to allow us to detect as few as 10 F5
19 Jurkat cells mixed with 10,000 untransduced Jurkat cells (Fig. 1c) . SABR signaling was rapid, as GFP signal was detectable within 3 h of co-incubation and reached saturation within 6-8 h ( Fig. 1d and Supplementary Fig. 2 ). Both sensitivity and kinetics were conserved for four different TCRs: EC27, FC4.3, FC5.5, and CP7.9, all of which recognize B27-KK10 19 . To test whether SABR signaling can be induced upon recognition of low-affinity TCRpMHC interactions, we used M1, an A2-MART1-specific TCR. The affinity of M1 TCR was too low to be measured by surface plasmon resonance as described previously 21 . F5 and M1 TCRs were indistinguishable in their ability to induce GFP signaling in NFAT-GFPJurkat cells expressing A2-MART1-SABR ( Supplementary Fig. 3 ). Taken together, these results show that SABRs can induce signaling upon successful and specific TCR-pMHC interaction, thereby allowing the identification of recognized antigen-presenting cells.
SABRs allow different modes of antigen presentation. Endogenous MHC presents epitopes from newly translated proteins or endocytosed proteins via cross-presentation. To test whether SABRs can also use these pathways for antigen presentation, we constructed an 'empty' version of SABRs that linked β 2-microglobulin with HLA-A2 or B27 but did not genetically encode for an epitope ( Supplementary  Fig. 4a ). We incubated NFAT-GFP-Jurkat cells expressing the empty SABRs with soluble MART1 or KK10 peptides, and cocultured them with Jurkat cells expressing F5 or EC27 TCRs. Both A2 and B27 empty SABRs induced a signal only in the presence of the soluble peptide corresponding to the TCRs. Moreover, the signal induced by correct peptide-TCR combinations was similar to the signal induced by the corresponding SABRs presenting covalently linked epitopes (Fig. 2a) . Next, we constructed pentameric tandem minigenes 22 (TMGs) to express the KK10 epitope along with four irrelevant cytomegalovirus-derived epitopes ( Supplementary Fig. 4a ). We cotransduced NFAT-GFP-Jurkat cells with the empty B27-SABR and the KK10 TMG. After co-incubation with Jurkat cells expressing EC27 or F5, the empty SABRs were able to present the endogenously expressed epitopes and induce specific signaling (Fig. 2b) . However, 
NATuRe MeTHoDS the overall signal was lower than that of the corresponding empty SABRs pulsed with soluble peptide. These results show that SABRs can present noncovalently linked epitopes generated through endogenous antigen-processing and antigen-presentation pathways.
SABRs initiate a bona fide TCR signal. SABRs use a CD3ζ -CD28 domain for intracellular signaling, similar to chimeric antigen receptors and TCRs. Therefore, we asked whether the intracellular signaling ability of SABRs is comparable to that of TCRs. We first tested whether SABRs induce early activation markers in NFAT-GFP-Jurkat cells. NFAT-GFP-Jurkat cells transduced with the B27-KK10-SABR expressed CD69 specifically upon coculture with Jurkat cells transduced with CP4.3 TCR, which implies that SABR signaling activates endogenous gene expression (Fig. 3a) . If SABRs induce a bona fide TCR signal, they should confer cytotoxic capabilities to primary T cells. We transduced activated primary T cells with A2-MART1-SABR and incubated them with CFSE-labeled target cells expressing F5 TCR. Transduced primary T cells lysed Jurkat cells or primary T cells expressing the F5 TCR specifically (Fig. 3b,c) . Next, we compared the antigen sensitivity of SABRs and TCRs. We transduced NFAT-GFP-Jurkat cells with either empty A2-SABR or F5 TCR, and used them as effectors. As targets, we used Jurkat cells transduced with A2-SABR or F5 TCR (Fig. 3d) . We cocultured effectors and targets in the presence of a range of concentrations of the MART1 peptide and then measured GFP expression. Antigen sensitivity was determined as the concentration of the peptide required for half-maximal signaling. The antigen sensitivity of SABRs was 30-fold lower than that of TCRs (Fig. 3e) . We also investigated the correlation between the functional avidity of TCR-pMHC interactions and signaling induced by SABRs. We first measured the functional avidity of EC27 TCR toward six variants of the KK10 peptide as described previously 19 .
We measured the ability of the EC27 TCR to induce GFP expression upon coculture with empty B27 SABRs pulsed with variants of the KK10 peptide. We observed a correlation between the functional avidity of TCR-pMHC interactions and SABR signaling. Notably, an ~180-fold reduction of functional avidity observed between the R2T and R2Q variants was still able to induce detectable SABR signaling ( Supplementary Fig. 4b ). Taken together, these results show that SABRs signal similarly to TCRs, albeit with lower antigen sensitivity.
Proof of concept of using SABR libraries for antigen discovery.
Next, we asked whether SABR libraries presenting a large number of epitopes can be used to screen for successful TCR-pMHC interactions.
We designed a strategy to construct and use SABR libraries for T-cellantigen-based discovery of 'orphan' TCRs with unknown antigens. First, we generated a list of target epitopes to encode 12,055 peptides (A2-SABR library) consisting of all known HLA-A*0201-restricted epitopes from the Immune Epitope Database 23 (Supplementary Table 3 ). We back-translated the protein sequences of the target epitopes to generate codon-optimized oligonucleotide sequences along with 15-bp overhangs that overlapped with the SABR vector. The entire list of oligonucleotides for the library was synthesized via pooled synthesis. The pooled library was then amplified and cloned by ligation-free cloning into the SABR vector plasmid (Supplementary Figs. 5 and 6a). The SABR libraries were packaged into lentiviral vectors and used to transduce NFAT-GFP-Jurkat cells. We first investigated whether the A2-SABR library allows for identification of the cognate antigen for F5 and SL9 TCRs. We transduced NFAT-GFP-Jurkat cells with the A2-SABR library and incubated them with Jurkat cells expressing the TCRs. After 10 h of coculture, we sorted GFP + CD69 + cells by FACS ( Supplementary Fig. 6b and Fig. 4a ) and extracted genomic DNA from them. We then amplified and sequenced the epitope portion of the SABRs ( Supplementary  Fig. 6c) , and aligned the sequencing reads with the SABR vector backbone by Burrows-Wheeler alignment 24 . Aligned reads were translated to their protein sequences, and the number of reads corresponding to each epitope was counted and reported in a list. We performed a minimum of three replicates of the co-incubation assay. For each replicate, a numerical rank was given to each epitope based on descending order of the number of reads. The rank from three replicates for each assay was averaged and reported as the 'average rank' (Supplementary Fig. 6c ). First, we plotted the average ranks of each of the epitopes from the SL9 sort against those from the F5 sort (Fig. 4b) . The top six epitopes in the F5 sort were analogs of ELAGIGILTV, which indicated successful identification of its antigen (Fig. 4c) . Six of the top ten epitopes from the SL9 sort were analogs of SLYNTAVATL (Fig. 4d) . The average fold enrichment of the top hits from the F5 and SL9 sorts compared with the mock sort was 296 and 70, respectively. The noise observed in the SL9 sort is possibly due to the higher number of analogs of the SLYNTVATL peptide. We compared the ranks of all the analogs of ELAGIGILTV and SLYNTVATL in the sorts. Six out of twenty-two ELAGIGILTV analogs were identified in the F5 sort ( Supplementary Fig. 7a ), whereas nine out of sixty SLYNTVATL analogs were identified in the SL9 sort ( Supplementary Fig. 7b ). The lack of identification of all the analogs is presumably due to reduced cross-reactivity of the 
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F5 or SL9 TCRs toward them. Indeed, analogs SLYNTIATL (V6I) and SLFNTVATL (Y3F) are documented escape mutations in the SLYNTVATL epitope 25, 26 . We validated the top six hits from the F5 sort by in vitro cytotoxicity assays. We observed that all six analogs of the MART1 peptide were specifically recognized by the F5 TCR, thus leading to the induction of cytotoxicity (Fig. 4e) . Nevertheless, these experiments showed that a SABR-library approach could identify the cognate antigen of a TCR via the screening of thousands of epitopes.
Personalized neoantigen discovery using SABRs. To further demonstrate the versatility of SABR libraries, we used a personalized approach for neoantigen discovery. A recent study identified a neoantigen-specific, tumor-reactive TCR from a person with melanoma by using DNA-barcoded tetramers. The identified TCR (neoTCR) recognizes a nonsynonymous mutation in the USP7 protein We generated a SABR library presenting 3,251 predicted HLA-A*0201-restricted epitopes (NeoAg-SABR library) corresponding to 108 nonsynonymous mutations found in the tumor (Supplementary Table 4) . We used the neoTCR as a surrogate for a tumor-reactive orphan TCR and used the NeoAg-SABR library to identify its antigen. We cocultured 
Articles

NATuRe MeTHoDS
Jurkat cells transduced with neoTCR and NFAT-GFP-Jurkat cells expressing the NeoAg-SABR library, sorted GFP + CD69 + cells, then sequenced and ranked epitopes from the sorted cells (Fig. 5a) . For each epitope, we plotted the average ranks from the neoTCR sort against those from the mock sort (Fig. 5b) . The top seven hits in the neoTCR sort were epitopes derived from USP7, demonstrating successful identification of the neoantigen by our approach (Fig. 5c) . The nonsynonymous D798Y mutation in USP7 was predicted to generate 30 overlapping neoepitopes, of which we identified 7 as cognate epitopes of neoTCR (Supplementary Fig. 8 ). To validate the seven detected epitopes, we constructed individual SABRs to present them. NFAT-GFP-Jurkat cells transduced with these SABRs induced GFP expression upon coculture with Jurkat cells expressing neoTCR (Fig. 5d) . Unexpectedly, the SABR presenting the nonmutant DLYHRVDVIF epitope also induced signaling upon recognition by neoTCR. Primary T cells transduced with neoTCR were able to specifically kill target cells pulsed with the peptides corresponding to seven detected neoepitopes, but not cells pulsed with the nonmutant peptide (Fig. 5e) . We posit that by covalently linking the nonmutant epitope, we may enforce its binding to MHC, unlike with peptide pulsing. This may lead to false identification of the nonmutant peptide as a 'hit' , but we expect subsequent validation by 
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Discussion
SABRs are modular proteins that combine antigen presentation and intracellular signaling, thereby allowing the detection of successful Rank in mock
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TCR-pMHC interactions and providing a platform for antigen discovery. In a companion study, we describe the use of trogocytosismediated membrane protein transfer for antigen discovery 27 . We envision use of the SABR-library approach for antigen discovery of antitumor CD8 + T cells (Supplementary Fig. 6 ). The flexibility of this approach allows for customizations required for antigen discovery for public or private TCRs. A SABR library based on shared tumor gene expression among people with a certain cancer can identify the antigen of a shared, public TCR, whereas a SABR library based on an individual's tumor mutanome can be used to interrogate the specificity of a private TCR. We have shown data specifically for HLA-A*0201 and HLA-B*2705, but SABRs can presumably be constructed for any class I HLA. Further testing and optimization may be required to expand the use of SABRs to all HLA-A, -B, and -C alleles from an individual. Furthermore, this approach can be used for antigen discovery for pathogen-reactive or self-reactive TCRs. Finally, we posit that SABRs based on class II MHC alleles will be able to signal similarly, and therefore could be used for antigen discovery of TCRs from CD4 + T cells. This will greatly aid antigen discovery for autoimmune CD4
+ T cells and regulatory T cells 28, 29 . Beyond antigen discovery, SABRs can also be purposed for different applications. SABR libraries incorporating variants of a single epitope may be used to interrogate TCR cross-reactivity and to identify altered peptide ligands or heteroclitic peptides 30 . The signaling ability of SABRs may also be used to impart functional attributes to primary T cells for therapeutic use. For instance, arming primary T cells with SABRs might allow them to eliminate autoreactive T cells via fratricide, or to suppress autoreactive T cells by inducing a tolerogenic signal 31 . Our approach presents several advantages over the current TCR-antigen-discovery techniques. The scale offered by SABRscurrently up to 10 6 epitopes-is considerably higher than that of a multimer or functional screen approach 32, 33 . SABR libraries do not rely on the synthesis of peptides or MHC molecules and are therefore far easier to construct, and unlike yeast display systems, they do not require the production of soluble TCRs 15 , which is technically challenging and nonrobust. Moreover, antigen discovery via yeast display requires several rounds of selection, outgrowth, and sequencing, whereas SABR libraries allow antigen discovery in a single, short-duration assay. Finally, SABR libraries do not require any specialized reagents, and can be used by any standard immunology laboratory with access to facilities for molecular cloning, cell culture, FACS, and high-throughput sequencing.
There are also some technical limitations of using SABR libraries. Unlike yeast display systems that can present up to 10 6 -10 8 epitopes 15 , SABRs are limited to 10 6 epitopes without requiring specialized cell-culture facilities. Because of this limitation, the optimal use of SABRs will still require ab initio knowledge of antigenic epitopes. In their current form, SABRs allow antigen discovery for a single TCR in one assay, unlike multimers. In the future, researchers might be able to increase this throughput by conducting the screen on primary T cell samples directly, by multiplexing sequencing samples, or by multiplexing SABR libraries. However, if primary T cells were to be used for screening, cytotoxicity induced by the primary T cells toward SABR-expressing cells would need to be mitigated for optimization of this approach. We are currently developing this technique for multiplexed neoantigen discovery at a higher scale. At the current scale, the SABR library screens described here did not yield false positive hits for F5 and NeoAg TCRs, but they did yield false positive hits identified in the SL9 sort. This indicates that further optimization may be required to reduce the false discovery rate and to improve the signal-to-noise ratio in atypical situations such as the case of the SL9 TCR. With the use of more sensitive and specific techniques, such as single-cell sorting and sequencing, the signal-to-noise ratio is expected to improve.
Collectively, we have demonstrated that SABR libraries are versatile and powerful tools for antigen discovery. The simplicity and scalability of SABRs will greatly aid the development of novel antigen-guided immunotherapies.
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Sample size
No particular methods were used to determine sample size. Most experiments rely on measuring the presence of signal above background. The background noise in our assays is minimal. Therefore we reasoned that having n=3 replications will be sufficient to distinguish signal from background noise.
Data exclusions No data exclusions
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All attempts at replication were successful Randomization Randomization is not relevant to our study because we have experimental arms that were constructed independently and not allocated from one pool of samples.
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Blinding was not possible/relevant. All the experimental arms were based on independently constructed cell lines/vectors. While making these cell lines/vectors, we had to know which arms they belonged to so that we could verify. E.g. while comparing F5 vs Mock TCR, we would verify that the F5 arm actually showed TCR expression before performing the experiment.
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